Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2016

Collaborative Arrangements

Schedule of revenue recognized from collaborative arrangements

	Year Ended December 31,
(In thousands)	2016		2015		2014
Mylan	$	15,102	$	19,175	$	—
Takeda Pharmaceuticals		15,075		—		—
Trek Therapeutics		—		8,216		—
Various VIBATIV collaborative partners		368		5,327		7,270
Other		500		—		—
Total revenue from collaborative arrangements	$	31,045	$	32,718	$	7,270

Summary of reductions to R&D costs related to the reimbursement payments

	Year Ended December 31,
(In thousands)	2016		2015		2014
Mylan	$	83,490	$	52,551	$	—
Alfa Wassermann		7,113		2,122		1,764
Other		134		483		120
Total reduction to R&D expense	$	90,737	$	55,156	$	1,884